A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third‐generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers - Noh, Young Su; Yoon, Seonghae; Kim, Suk Ran; Lee, Kyung‐Tae; Jang, In‐Jin (Basic & clinical pharmacology & toxicology, 2019)
Keywords: Absorption; Administration, Oral; Adult; Area Under Curve; Asian Continental Ancestry Group; Copy number; DNA Copy Number Variations; Dose-Response Relationship, Drug; Epidermal growth factor receptors; ErbB Receptors; European Continental Ancestry Group; Food intake; Food-Drug Interactions; Gene polymorphism; Genotypes; Glutathione; Glutathione Transferase - genetics; Glutathione Transferase - metabolism; GSTM1 gene; GSTM1 protein; GSTM3 gene; Half-Life; Healthy Volunteers; Humans; Male; Mathematical models; Metabolism; Middle Aged; Nucleotides; olmutinib; Oral administration; Parameters; Pharmacogenomics; Pharmacokinetics; Pharmacology; Piperazines - administration & dosage; Piperazines - adverse effects; Piperazines - pharmacokinetics; Polymorphism; Polymorphism, Single Nucleotide; population pharmacokinetics; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Race; Safety; Young Adult; olmutinib; pharmacokinetics; pharmacogenomics; population pharmacokinetics